| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/02/2009 | EP2125725A1 Compounds of formula (i) as serine protease inhibitors |
| 12/02/2009 | EP2125724A1 Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists |
| 12/02/2009 | EP2125722A2 Bi-aryl or aryl-heteroaryl substituted indoles |
| 12/02/2009 | EP2125721A1 Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders |
| 12/02/2009 | EP2125720A1 Indole and benzothiophene compounds as modulators of the histamine h3 receptor |
| 12/02/2009 | EP2125719A1 Bazedoxifene bis-phosphorates |
| 12/02/2009 | EP2125718A2 New substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions |
| 12/02/2009 | EP2125714A1 Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide |
| 12/02/2009 | EP2125712A1 Novel protein kinase modulators and therapeutic uses thereof |
| 12/02/2009 | EP2125711A1 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
| 12/02/2009 | EP2125704A1 N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
| 12/02/2009 | EP2125702A1 Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| 12/02/2009 | EP2125700A1 L-carnitine calcium fumarate, preparation method and application for the same |
| 12/02/2009 | EP2125697A1 Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates |
| 12/02/2009 | EP2125695A2 Nitric oxide donor compounds |
| 12/02/2009 | EP2125683A1 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders |
| 12/02/2009 | EP2125036A1 Formation and rejuvenation of organs and alcohol damaged organ regeneration through stem cell nutrients |
| 12/02/2009 | EP2125023A2 Soluble forms of inclusion complexes of histone deacetylase inhibitors and cyclodextrins, their preparation processes and uses in the pharmaceutical field |
| 12/02/2009 | EP2124985A2 Methods and compositions for treating neuropathies |
| 12/02/2009 | EP2124977A1 Method for treating or preventing systemic inflammation |
| 12/02/2009 | EP2124968A1 Compositions and methods for the treatment of muscle wasting |
| 12/02/2009 | EP2124967A2 Compositions and methods for treating hematopoietic malignancies |
| 12/02/2009 | EP2124966A2 Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts |
| 12/02/2009 | EP2124965A1 Methods for preventing and treating neurodegenerative disorders |
| 12/02/2009 | EP2124964A1 Polymer-linked-bisphosphonate inhalant formulations and methods for using the same |
| 12/02/2009 | EP2124962A1 Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions |
| 12/02/2009 | EP2124961A2 Novel composition based on cholest-4-ene-3-one oxime |
| 12/02/2009 | EP2124960A1 3-hydroxychlormadinone acetate for the topical treatment of androgen-dependent skin diseases |
| 12/02/2009 | EP2124959A1 Pharmaceutical composition |
| 12/02/2009 | EP2124957A1 Methods of treating mood disorders |
| 12/02/2009 | EP2124956A1 Use of 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic m1, m2 and m3 receptors |
| 12/02/2009 | EP2124955A2 Inhibition of pde2a |
| 12/02/2009 | EP2124953A1 Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same |
| 12/02/2009 | EP2124951A1 5-cyan0-4- (pyrrolo ý2, 3b¨pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| 12/02/2009 | EP2124950A1 Treatment of pain with naloxone |
| 12/02/2009 | EP2124949A1 Pharmaceutical formulation |
| 12/02/2009 | EP2124948A1 Compositions for treating hyperproliferative vascular disorders and cancers |
| 12/02/2009 | EP2124947A1 Dosage regimen for comt inhibitors |
| 12/02/2009 | EP2124946A1 The use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection |
| 12/02/2009 | EP2124945A1 Method of providing pirfenidone therapy to a patient |
| 12/02/2009 | EP2124943A1 Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors |
| 12/02/2009 | EP2124939A1 A method for improving the pharmacokinetics of drugs metabolized by ugt2b10 |
| 12/02/2009 | EP2124938A1 Topical formulation |
| 12/02/2009 | EP2124936A2 Porphyrin activation by different spectrum electromagnetical waves-new malignant tumour treatment possibilities |
| 12/02/2009 | EP2124934A2 Cosmetic and pharmaceutical applications of n-acetylhydroxyproline |
| 12/02/2009 | EP2124933A1 Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| 12/02/2009 | EP2124932A2 Use of compounds of the milbemycin family for the treatment of dermatological disorders in human beings |
| 12/02/2009 | EP2124931A1 Pharmaceutical compositions comprising nebivolol or a nebivolol analogue |
| 12/02/2009 | EP2124930A1 Isosorbide mononitrate derivatives for the treatment of intestinal disorders |
| 12/02/2009 | EP2124929A1 A two-component taxane containing pharmaceutical composition |
| 12/02/2009 | EP2124928A1 Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by pbr, cb2, and nk2 receptors |
| 12/02/2009 | EP2124926A1 Treatment for respiratory disease |
| 12/02/2009 | EP2124924A1 Active ingredient combination of a retinoid and a hormone combination with contraceptive action as medicament for treatment of skin diseases |
| 12/02/2009 | EP2124923A1 Use of a polyphenol in the treatment of the metabolic syndrome and endothelial dysfunction or other vascular sequellae. |
| 12/02/2009 | EP2124921A2 Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
| 12/02/2009 | EP2124919A2 Methods for modulating bone formation and mineralization |
| 12/02/2009 | EP2124917A1 Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders |
| 12/02/2009 | EP2124914A2 Method and system for enhancing self-treatment of onychomycosis |
| 12/02/2009 | EP2124910A2 Targeting of ews-fli1 as anti-tumor therapy |
| 12/02/2009 | EP2124908A1 Compounds and uses thereof |
| 12/02/2009 | EP2124904A1 Stable sustained release formulations of fluvastatin |
| 12/02/2009 | EP2124903A1 Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent |
| 12/02/2009 | EP2124901A1 Tablet preparation without causing a tableting trouble |
| 12/02/2009 | EP2124900A2 Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
| 12/02/2009 | EP2124896A2 Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
| 12/02/2009 | EP2124893A1 Pharmaceutical compositions comprising a calcilytic agent |
| 12/02/2009 | EP2124892A2 Use of a highly emulsified silicone oil (hes) for the production of a medicament |
| 12/02/2009 | EP2124891A1 Controlled release preparation containing cilostazoland process for the preparation thereof |
| 12/02/2009 | EP2124887A2 -lactam-containing formulations having increased stability in aqueous solution |
| 12/02/2009 | EP2124886A2 Oxaliplatin pharmaceutical composition with alcoholic sugar-based buffer |
| 12/02/2009 | EP2124884A2 Compositions comprising bile acid sequestrants for treating esophageal disorders |
| 12/02/2009 | EP2124881A1 Ciclesonide containing sterile aqueous suspension |
| 12/02/2009 | EP2124879A2 Processes for making cyclic lipid implants for intraocular use |
| 12/02/2009 | EP2124878A1 Increased effectiveness of allylamine drug compounds |
| 12/02/2009 | EP2124637A2 Stabilized anthocyanin compositions |
| 12/02/2009 | EP2124616A1 Paromomycin supplemented feedingstuffs for poultry species and use thereof for prophylaxis of histomoniasis, reduction of the horizontal spreading of histomoniasis, and for improved weight gain and feed conversion |
| 12/02/2009 | EP2124575A2 Antimicrobial compositions |
| 12/02/2009 | EP2124569A2 Formulations for parenteral administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones |
| 12/02/2009 | EP2124565A2 N-substituted glycine derivatives: hydroxylase inhibitors |
| 12/02/2009 | EP2124562A1 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| 12/02/2009 | EP2124560A1 2-aminopyrimidine modulators of the histamine h4 receptor |
| 12/02/2009 | EP2124558A2 Substituted 1,3-dioxanes and their uses |
| 12/02/2009 | EP2124555A2 Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| 12/02/2009 | EP2124554A1 Compositions and methods for the treatment of cancer |
| 12/02/2009 | EP2124553A1 Method for treating and preventing arthritis |
| 12/02/2009 | EP2124552A1 Extended release pharmaceutical formulations of s-adenosylmethionine |
| 12/02/2009 | EP2124551A2 Substituted 1,3-dioxanes and their uses |
| 12/02/2009 | EP2124550A1 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| 12/02/2009 | EP2124549A1 Anti-hypercholesterolemic compounds |
| 12/02/2009 | EP1965805B1 Urea derivatives useful as calcium receptor modulators |
| 12/02/2009 | EP1951274B1 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer |
| 12/02/2009 | EP1863785B1 Novel thiophene sulfoximines for treating complement-mediated diseases and conditions |
| 12/02/2009 | EP1861360B1 Pyrrolidine derivatives as histamine h3 receptor antagonists |
| 12/02/2009 | EP1856093B1 (2R,4aR,10bR)-6-(2,6-dimethoxypyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol, HCl salt |
| 12/02/2009 | EP1753732B1 Phenyl-sulfamates as aromatase inhibitors |
| 12/02/2009 | EP1737859B1 Novel crystalline form of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo¬4.3.0 nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid |
| 12/02/2009 | EP1696737B1 Edible compositions which are adapted for use by a companion animal |
| 12/02/2009 | EP1666043B1 Product containing prostaglandin |
| 12/02/2009 | EP1664029B1 Quinazoline derivatives as antitumor agents |
| 12/02/2009 | EP1663220B1 Novel process for the preparation of pleuromutilin derivatives |